Cellular uptake of apidaecin 1b and related analogs in gram-negative bacteria reveals novel antibacterial mechanism for proline-rich antimicrobial peptides

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 391-398

  Berthold, Nicole ^a   Hoffmann, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antimicrobial peptide (AMP); Confocal fluorescence microscopy; Escherichia coli; Klebsiella pneumoniae; Proline rich peptides

Indexed keywords

6 CARBOXYFLUORESCEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE RICH ANTIMICROBIAL PEPTIDE APIDAECIN 1B; PROLINE RICH ANTIMICROBIAL PEPTIDE APIDAECIN API134; PROLINE RICH ANTIMICROBIAL PEPTIDE APIDAECIN API137; PROLINE RICH ANTIMICROBIAL PEPTIDE APIDAECIN API155; PROLINE RICH ANTIMICROBIAL PEPTIDE APIDAECIN API88; PROTEIN DNAK; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG LABELING; DRUG SCREENING; DRUG STRUCTURE; DRUG UPTAKE; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GRAM NEGATIVE BACTERIUM; GROWTH INHIBITION; HONEYBEE; INTERNALIZATION; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROCESS OPTIMIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MOLECULAR SEQUENCE DATA; PROLINE;

EID: 84896321273     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660104     Document Type: Article

References (27)

1. Boucher, H.W.; Talbot, G.H.; Benjamin, D.K., Jr.; Bradley, J.; Guidos, R.J.; Jones, R.N.; Murray, B.E.; Bonomo, R.A.; Gilbert, D. 10 x '20 Progress - Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America. Clin. Infect. Dis., 2013, 56(12), 1685-94.
2. Shlaes, D.M. New β-lactam-β -lactamase inhibitor combinations in clinical development. Ann. NY Acad. Sci., 2013, 1277, 105-114.
3. Haney, E.F.; Hancock, R.B.E.W. Peptide design for antimicrobial and immunomodulatory applications. Biopolymers, 2013, 100(6), 572-83.
4. Brogden, K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol., 2005, 3(3), 238-250.
5. Scocchi, M.; Tossi, A.; Gennaro, R. Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cell. Mol. Life Sci., 2011, 68(13), 2317-2330.
6. Otvos, L. Antibacterial peptides isolated from insects. J. Pept. Sci., 2000, 6(10), 497-511.
7. Otvos, L. The short proline-rich antibacterial peptide family. Cell. Mol. Life Sci., 2002, 59(7), 1138-1150.
8. Benincasa, M.; Pelillo, C.; Zorzet, S.; Garrovo, C.; Biffi, S.; Gennaro, R.; Scocchi, M. The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol., 2010, 10(1), 178.
9. Peters, B.M.; Shirtliff, M.E.; Jabra-Rizk, M.A. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog., 2010, 6(10), e1001067.
10. Mattiuzzo, M.; Bandiera, A.; Gennaro, R.; Benincasa, M.; Pacor, S.; Antcheva, N.; Scocchi, M. Role of the Escherichia coli SbmA in the antimicrobial activity of proline-rich peptides. Mol. Microbiol., 2007, 66(1), 151-163.
11. Otvos, L.; O, I.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry, 2000, 39(46), 14150-14159.
12. Zhou, Y.; Chen, W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of cytoplasmic protein profile in Escherichia coli incubated with apidaecin IB. J. Proteomics, 2011, 75(2), 511-6.
13. Zhou, Y.; Chen, W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of membrane protein profile in Escherichia coli incubated with apidaecin IB. PLoS ONE, 2011, 6(6), e20442.
14. Ostorhazi, E.; Holub, M.C.; Rozgonyi, F.; Harmos, F.; Cassone, M.; Wade, J.D.; Otvos, L. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int. J. Antimicrob. Agents, 2011, 37(5), 480-484.
15. Knappe, D.; Fritsche, S.; Alber, G.; Kohler, G.; Hoffmann, R.; Muller, U. Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model. J. Antimicrob. Chemother., 2012, 67(10), 2445-2451.
16. Ostorházi, E.; Nemes-Nikodém, É.; Knappe, D.; Hoffmann, R. In vivo activity of optimized apidaecin and oncocin peptides against a multiresistant, KPC producing Klebsiella pneumoniae strain. Protein Pept. Lett., 2013, [Epub ahead of print].
17. Otvos Jr., L.; Flick-Smith, H.; Fox, M.; Ostorhazi, E.; Dawson, R.M.; Wade, J.D. The designer proline-rich antibacterial peptide A3-APO prevents bacillus anthracis mortality by deactivating bacterial toxins. Protein Pept. Lett., 2013, [Epub ahead of print].
18. Czihal, P.; Knappe, D.; Fritsche, S.; Zahn, M.; Berthold, N.; Piantavigna, S.; Müller, U.; van Dorpe, S.; Herth, N.; Binas, A.; Köhler, G.; Spiegeleer, B. de; Martin, L.L.; Nolte, O.; Sträter, N.; Alber, G.; Hoffmann, R. Api88 is a novel antibacterial designer Peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chem. Biol., 2012, 7(7), 1281-1291.
19. Berthold, N.; Czihal, P.; Fritsche, S.; Sauer, U.; Schiffer, G.; Knappe, D.; Alber, G.; Hoffmann, R. Novel apidaecin 1b analogs with superior serum stabilities for treatment of Gram-negative pathogens. Antimicrob. Agents Chemother., 2012, 57, 402-409.
20. Zahn, M.; Berthold, N.; Kieslich, B.; Knappe, D.; Hoffmann, R.; Strater, N. Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK. J. Mol. Biol., 2013, 425(14), 2463-79.
21. Piantavigna, S.; Czihal, P.; Mechler, A.; Richter, M.; Hoffmann, R.; Martin, L.L. Cell penetrating apidaecin peptide interactions with biomimetic phospholipid membranes. Int. J. Pept. Res. Ther., 2009, 15(2), 139-146.
22. Knappe, D.; Zahn, M.; Sauer, U.; Schiffer, G.; Sträter, N.; Hoffmann, R. Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the highresolution structure of the oncocin-DnaK complex. Chembiochem, 2011, 12(6), 874-876.
23. Otvos, L. Jr.; Bokonyi, K.; Varga, I.; Otvos, B.I.; Hoffmann, R.; Ertl, H.C.J.; Wade, J.D.; McManus, A.M.; Craik, D.J.; Bulet, P. Insect peptides with improved protease-resistance protect mice against bacterial infection. Protein Sci., 2000, 9, 742-749.
24. Castle, M.; Nazarian, A.; Yi, S.S.; Tempst, P. Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. J. Biol. Chem., 1999, 274(46), 32555-32564.
25. Matsumoto, K.; Orikasa, Y.; Ichinohe, K.; Hashimoto, S.; Ooi, T.; Taguchi, S. Flow cytometric analysis of the contributing factors for antimicrobial activity enhancement of cell-penetrating type peptides: case study on engineered apidaecins. Biochem. Biophys. Res. Commun., 2010, 395(1), 7-10.
26. Genevaux, P.; Georgopoulos, C.; Kelley, W.L. The Hsp70 chaperone machines of Escherichia coli: a paradigm for the repartition of chaperone functions. Mol. Microbiol., 2007, 66(4), 840-857.
27. Liebscher, M.; Haupt, K.; Yu, C.; Jahreis, G.; Lucke, C.; Schiene-Fischer, C. Rational design of novel peptidic DnaK ligands. Chembiochem, 2010, 11(12), 1727-1737.